In consideration of their response, our intention is to file for Conditional Approval of Multikine with Breakthrough Therapy designation based on our completed Phase 3 data,” stated CEL-SCI CEO ...

The BCMA-targeting CAR-T – also known as cilta-cel – has been filed with the EMA as a treatment for adults with relapsed/refractory multiple myeloma, an incurable form of blood cancer ...

In consideration of their response, our intention is to file for Conditional Approval of Multikine with Breakthrough Therapy designation based on our completed Phase 3 data," stated CEL-SCI CEO Geert ...